EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Artia Global Partners LP

Artia Global Partners LP grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 216,700 shares of the company's stock after buying an additional 60,400 shares during the period. EyePoint Pharmaceuticals accounts for 0.6% of Artia Global Partners LP's holdings, making the stock its 24th biggest position. Artia Global Partners LP owned 0.32% of EyePoint Pharmaceuticals worth $1,614,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Summit Investment Advisors Inc. raised its stake in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after acquiring an additional 1,940 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth about $59,000. Virtus ETF Advisers LLC purchased a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth about $67,000. AlphaQuest LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after purchasing an additional 9,670 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in EyePoint Pharmaceuticals during the 4th quarter valued at approximately $76,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Up 2.7 %

Shares of EyePoint Pharmaceuticals stock traded up $0.19 during mid-day trading on Friday, reaching $7.32. 278,296 shares of the stock traded hands, compared to its average volume of 883,057. The stock has a market capitalization of $503.70 million, a PE ratio of -3.66 and a beta of 1.39. The business has a 50-day moving average of $5.98 and a 200 day moving average of $7.70. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $21.26.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. On average, equities research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EYPT has been the topic of several analyst reports. Citigroup assumed coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.